Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood Rev. 2016 Sep;30(5):381-8. doi: 10.1016/j.blre.2016.04.006. Epub 2016 Apr 25.

Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?

Author information

1
Leukemia Program, Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
2
Section of Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA.
3
Section of Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA. Electronic address: amer.zeidan@yale.edu.

Abstract

Chronic myelomonocytic leukemia (CMML) is a unique disease entity with overlap components of both myelodysplastic syndrome and myeloproliferative neoplasms. CMML is a clonal hematopoietic stem cell neoplasm characterized by monocytosis, cytopenias, and extramedullary manifestations such as splenomegaly. The disease is rare and has undergone revisions in its classification. We review the recent classification strategies as well as diagnostic criteria, focusing on the new insights into the genetic alterations and unique pathophysiology of the disease. We also discuss the latest molecular characterization of the disease, including how molecular factors affect current prognostic models. Finally, we focus on available treatment strategies, with a special emphasis on experimental and forthcoming therapies.

KEYWORDS:

Chronic myelomonocytic leukemia; MDS; Myeloprolifrative neoplasm

PMID:
27162201
DOI:
10.1016/j.blre.2016.04.006
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center